Background: Parents are faced with a vaccination decision in the context of their own vaccination and that of their children with a COVID-19 vaccine. At present, there is no (complete) vaccination recommendation.
Research Question: The study investigates the willingness to vaccinate of parents of minors and people without children who are minors, in which gender differences in particular are examined.
Methods: The study is based on a random sample (telephone survey, = 2,014, collected between 12 November and 10 December 2020). The evaluation is primarily based on the sub-sample of people with minors in the household ( = 461).
Results: Parents of minors consistently show a lower willingness to be vaccinated with a COVID-19 vaccine than respondents without minors (54.1% vs 71.1%). Fathers show a stronger willingness to be vaccinated than mothers. Furthermore, men are more willing to get their own child vaccinated with a COVID-19 vaccine than are women.
Conclusions: Among parents and especially mothers, a considerable misrepresentation of vaccination risks and frequent beliefs in vaccination conspiracy theories can be observed. Clear and easily understandable information on the effects and side effects of vaccination with a COVID-19 vaccine by relevant institutions and physicians is recommended.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485570 | PMC |
| http://dx.doi.org/10.1007/s00608-021-00925-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.
NPJ Vaccines
October 2024
Centre for Clinical Trial, Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Malaysia.
Article Synopsis
- - This clinical trial compared the safety and effectiveness of an inhaled COVID-19 vaccine (Ad5-nCoV-IH) against an intramuscular vaccine (BNT-IM) in 540 vaccinated adults in Malaysia from September 2022 to May 2023.
- - While Ad5-nCoV-IH exhibited lower immunogenicity (with a GMC ratio of 0.22) compared to BNT-IM, it resulted in fewer adverse drug reactions (39.26% vs. 64.68%) and no serious side effects were documented.
- - Both vaccines demonstrated similar efficacy against COVID-19 variants, but the study concluded that Ad5-nCoV-IH did not meet the non
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.
Curr Oncol
April 2024
Life Saving Therapies Network, Ottawa, ON K1H 5E6, Canada.
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost.
View Article and Find Full Text PDFProbing delivery of a lipid nanoparticle encapsulated self-amplifying mRNA vaccine using coherent Raman microscopy and multiphoton imaging.
Sci Rep
February 2024
GSK Center for Optical Molecular Imaging, University of Illinois Urbana-Champaign, Urbana, IL, USA.
The COVID-19 pandemic triggered the resurgence of synthetic RNA vaccine platforms allowing rapid, scalable, low-cost manufacturing, and safe administration of therapeutic vaccines. Self-amplifying mRNA (SAM), which self-replicates upon delivery into the cellular cytoplasm, leads to a strong and sustained immune response. Such mRNAs are encapsulated within lipid nanoparticles (LNPs) that act as a vehicle for delivery to the cell cytoplasm.
View Article and Find Full Text PDFNirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
Lancet Infect Dis
July 2023
Department of Paediatrics, University Medical Centre Utrecht, Utrecht, Netherlands; ReSViNET foundation, Zeist, Netherlands.
Article Synopsis
- Nirsevimab, a long-lasting monoclonal antibody developed to protect infants from RSV, shows great potential due to the high conservation of its binding site, although the emergence of escape variants needs further investigation from 2015 to 2021.
- The study analyzed RSV A and B prevalence across multiple global surveillance studies, revealing that most amino acids in the nirsevimab binding site remained stable, with only a notable polymorphism (Ile206Met:Gln209Arg) appearing in RSV B after 2016.
- The researchers found that nirsevimab effectively neutralizes various RSV strains, including some with binding-site changes, although certain RSV B variants showed reduced sensitivity to nirsevim
SARS-CoV-2 Spike Protein Downregulates Cell Surface α7nAChR through a Helical Motif in the Spike Neck.
ACS Chem Neurosci
February 2023
Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
A deficiency of the functional α7 nicotinic acetylcholine receptor (α7nAChR) impairs neuronal and immune systems. The SARS-CoV-2 spike protein (S12) facilitates virus cell entry during COVID-19 infection and can also independently disrupt cellular functions. Here, we found that S12 expression significantly downregulated surface expression of α7nAChR in mammalian cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!